Assembly Biosciences
ASMB
98 hedge funds and large institutions have $430M invested in Assembly Biosciences in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 31 reducing their positions, and 15 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 31
25% more capital inflows, than outflows
Capital inflows: $62.9M | Capital outflows: $50.2M
1.78% more ownership
Funds ownership: 86.98% → 88.76% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
2% less funds holding
Funds holding: 100 → 98 (-2)
19% less call options, than puts
Call options by funds: $3.39M | Put options by funds: $4.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$23.2M |
| 2 |
BlackRock
New York
|
+$5.55M |
| 3 |
EcoR1 Capital
San Francisco,
California
|
+$3.62M |
| 4 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.87M |
| 5 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$7.72M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$3.85M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.93M |
| 4 |
Renaissance Technologies
New York
|
-$2.72M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.69M |
ASMB Hedge Fund Activity: Q1 2020 in Review
98 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2020, worth a combined $430M — down 25% from $576M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ASMB and 14 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 40 added.
The largest buyer was Consonance Capital Management, adding an estimated $23.2M. The largest seller was Armistice Capital, cutting an estimated $7.72M.
- 98 institutional investors held Assembly Biosciences (ASMB) as of Q1 2020, down from 100 in Q4 2019.
- Funds reported $430M of Assembly Biosciences stock for Q1 2020, down 25% quarter-over-quarter.
- 14 funds opened new Assembly Biosciences positions in Q1 2020 and 15 closed out, a net change of -1 holder.
- The largest Assembly Biosciences buyer in Q1 2020 was Consonance Capital Management, an estimated $23.2M added.
- The largest Assembly Biosciences seller in Q1 2020 was Armistice Capital, an estimated $7.72M sold.
Based on aggregated 13F filings for Q1 2020.